Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Depreciation and Depletion: 2020-2024

Historic Depreciation and Depletion for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to $86,116.

  • Immuneering's Depreciation and Depletion fell 4.05% to $86,116 in Q4 2024 from the same period last year, while for Dec 2024 it was $355,807, marking a year-over-year increase of 10.22%. This contributed to the annual value of $355,807 for FY2024, which is 10.22% up from last year.
  • Immuneering's Depreciation and Depletion amounted to $86,116 in Q4 2024, which was down 3.18% from $88,949 recorded in Q3 2024.
  • Over the past 5 years, Immuneering's Depreciation and Depletion peaked at $90,533 during Q2 2024, and registered a low of $5,307 during Q2 2020.
  • Its 3-year average for Depreciation and Depletion is $77,152, with a median of $78,268 in 2023.
  • In the last 5 years, Immuneering's Depreciation and Depletion spiked by 468.33% in 2022 and then dropped by 4.05% in 2024.
  • Over the past 5 years, Immuneering's Depreciation and Depletion (Quarterly) stood at $7,449 in 2020, then soared by 98.89% to $14,815 in 2021, then soared by 418.81% to $76,862 in 2022, then rose by 16.77% to $89,754 in 2023, then declined by 4.05% to $86,116 in 2024.
  • Its Depreciation and Depletion was $86,116 in Q4 2024, compared to $88,949 in Q3 2024 and $90,533 in Q2 2024.